CliffBio
small molecule

ERYC SPRINKLES

ERYTHROMYCIN

Loss of exclusivity—loss of exclusivity
CompanyHospira →See this company's full patent-cliff portfolio

Drug detail

Brand nameERYC SPRINKLES
Active ingredientERYTHROMYCIN
Strength125MG
Dosage formCAPSULE, DELAYED REL PELLETS
RouteORAL
ModalitySmall molecule
FDA approvalJuly 1985
Marketing statusDISCN

More from Hospira

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ERYC SPRINKLES patent cliff — loss of exclusivity — | CliffBio